Treatment change | n | % |
Major changes | 67 | 53.2 |
Conversion to targeted treatment | 40 | 31.7 |
ADT > RT | 12 | 9.5 |
AS > RT | 10 | 7.9 |
ADT > RT+ADT | 6 | 4.8 |
AS > RT+ADT | 5 | 4.0 |
Biopsy > RT | 2 | 1.6 |
Biopsy > RT+ADT | 2 | 1.6 |
Biopsy > cryoablation | 1 | 0.8 |
RT+ADT > surgery | 1 | 0.8 |
Sipuleucel-T > RT | 1 | 0.8 |
Conversion to systemic treatment | 12 | 9.5 |
AS > ADT | 5 | 4.0 |
RT+ADT > ADT monotherapy | 2 | 1.6 |
RT > ADT | 2 | 1.6 |
AS > abiraterone | 1 | 0.8 |
Surgery > ADT | 1 | 0.8 |
Biopsy > ADT | 1 | 0.8 |
Conversion to AS | 10 | 7.9 |
RT+ADT > AS | 4 | 3.2 |
ADT > AS | 4 | 3.2 |
RT > AS | 2 | 1.6 |
Miscellaneous | 5 | 4.0 |
Surgery > RT+ADT | 2 | 1.6 |
RT+ADT > cryoablation | 1 | 0.8 |
RT+ADT > RT+ADT+chemotherapy | 1 | 0.8 |
ADT > PSMA RLT | 1 | 0.8 |
Minor changes | 8 | 6.4 |
RT > RT+ADT | 5 | 4.0 |
RT+ADT > RT | 3 | 2.4 |
ADT = androgen-deprivation therapy; AS = active surveillance; RLT = radioligand therapy.